Monday, December 10, 2018
– The Harrington Discovery Institute
at University Hospitals in Cleveland, Ohio, today announced the 2019 Harrington Scholar-Innovator Award recipients. The projects supported by the awards include new therapeutics to treat metabolic disorders, autoimmune disorders and cancer, and new approaches to eradicate parasitic diseases in developing countries.
The Harrington Discovery Institute—part of The Harrington Project for Discovery & Development—is designed to translate science of great promise into therapeutics that can impact human health. Award recipients whose research demonstrates innovation, creativity and the potential to impact standards of care in medicine are selected from institutions across the U.S. In addition to financial support, the Harrington Discovery Institute provides expertise and oversight in all aspects of drug development.
“Every year we see novel and creative approaches for treating major unmet medical needs. This year was no exception. The 2019 Scholar-Innovator class represents an exciting portfolio of drugs-in-the-making with potential to significantly improve human health. We are honored to support these extraordinary physician-scientists,” Jonathan S. Stamler, MD, President of the Harrington Discovery Institute.
The selected scholars have access to several rounds of capital (up to a total of $700,000) through their affiliation with the Harrington Discovery Institute to support the transition of their work into the private sector. Scholars are then free to approach investors of their choice to support the commercialization of their work. They also have facilitated access to BioMotiv, the mission-aligned development company that is part of The Harrington Project.
“Our new class of scholars was selected from a large pool of highly qualified individuals from across the U.S. With this year’s class, we have supported over 100 Harrington Scholars,” said Mukesh K. Jain, MD, Chief Scientific Officer of the Harrington Discovery Institute.